FAQ/Help |
Calendar |
Search |
Today's Posts |
07-08-2009, 07:45 PM | #1 | ||
|
|||
Senior Member
|
Dr. Susan Duty is presenting her work on glutamate this week at the University of Edinburgh...here's the link:
http://www.sciencedaily.com/releases...0707201222.htm I especially like this comment: "We also have good evidence now that stimulating these receptors can provide protection to the dopamine-containing nerve cells in preclinical models of Parkinson's disease and that the protected nerve cells function normally and are able to help restore movement control." Encouraging, no? Does anyone know exactly what "preclinical models of PD" means-people, primate, or rodent? Someone or somewhere I read that it means people, but surely that cannot be correct (although it'd be great if it were!) |
||
Reply With Quote |
07-09-2009, 01:09 AM | #2 | ||
|
|||
Member
|
[utamate this week at the University of Edinburgh...here's the link:
[url]hQUOTE=lurkingforacure;534725]Dr. Susan Duty is presenting her work on glttp://www.sciencedaily.com/releases/2009/07/ Does anyone know exactly what "preclinical models of PD" means-people, primate, or rodent? Someone or somewhere I read that it means people, but surely that cannot be correct (although it'd be great if it were!)[/QUOTE Preclinical models: usually means mice and other rodents |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
monosodium glutamate (msg) | Parkinson's Disease | |||
Glutamate identified as predictor of disease progression in multiple sclerosis (Topix | Multiple Sclerosis | |||
Targeting glutamate receptors | Parkinson's Disease | |||
FP0011 can be a potent, safe glutamate release inhibitor | Parkinson's Disease |